Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||DPV-001 + INCAGN01876 + Retifanlimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DPV-001||DPV 001|DPV001||DPV-001 is a cancer vaccine consisting of dendritic cell targeting microvesicles (DRibbles), which are autophagosomes derived from two non-small cell lung carcinoma cell lines (UbiLT3 and UbiLT6) that contain numerous tumor-associated antigens, including DAMPs, and delivers stable short-lived proteins (SLiPs) and defective ribosomal products (DRiPs), potential resulting in the induction of antitumor immune response (JITC 2015; 3(Suppl 2): P435; JITC 2013; 1(Suppl 1): P260).|
|INCAGN01876||INCAGN1876|INCAGN-1876|INCAGN 1876||GITR Antibody 6||INCAGN01876 is an activating monoclonal antibody that binds to the glucocorticoid-induced tumor necrosis factor receptor, TNFRSF18 (GITR, CD357), which leads to activation of GITR and potentially results in activation of anti-tumor immunity (NCI Drug Dictionary).|
|Retifanlimab||MGA 012|INCMGA00012|MGA012||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 86||Retifanlimab (INCMGA00012) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04470024||Phase I||DPV-001 + INCAGN01876 + Retifanlimab DPV-001 + Retifanlimab||Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC||Recruiting||USA||0|